HIMS Stock Tumbles: Here's Why It's a Buy Right Now
https://www.zacks.com/commentary/2295212/hims-stock-tumbles-here-s-why-it-s-a-buy-right-now?cid=CS-ZC-FT-investment_ideas-2295212
Jun 28, 2024 - Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
0
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
https://www.zacks.com/stock/news/2294903/pharma-stock-roundup-fda-s-crl-to-mrk-abbv-phase-iii-study-failures-for-nvo-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-2294903
Jun 28, 2024 - FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
0
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2294618/novo-nordisk-nvo-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2294618
Jun 27, 2024 - In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.
0
Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal
https://www.zacks.com/stock/news/2294455/novo-nordisk-s-nvo-hypertension-drug-study-fails-to-meet-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2294455
Jun 27, 2024 - Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.
0
Pfizer's Working on the Next Wegovy, but Can It Beat Novo Nordisk?
https://www.fool.com/investing/2024/06/25/pfizers-working-on-the-next-wegovy-but-can-it-beat/?source=iedfolrf0000001
Jun 25, 2024 - This is a matchup that the latecomer might not be able to win.
0
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
https://www.zacks.com/stock/news/2292821/why-novo-nordisk-nvo-is-a-top-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2292821
Jun 25, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
0
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
https://www.fool.com/investing/2024/06/21/the-best-could-be-yet-to-come-for-novo-nordisk/?source=iedfolrf0000001
Jun 21, 2024 - Novo Nordisk's stock may look expensive but not if you focus on the long term.
0
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
https://www.zacks.com/stock/news/2290782/here-s-why-eli-lilly-lly-is-probably-the-best-drug-stock-now?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2290782
Jun 20, 2024 - Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
0
The Best Biotech Stock to Invest $1,000 in Right Now
https://www.fool.com/investing/2024/06/18/the-best-biotech-stock-to-invest-1000-in-right-now/?source=iedfolrf0000001
Jun 18, 2024 - This stock may not be a slam dunk, but it's looking very promising.
0
Could Structure Therapeutics Become the Next Novo Nordisk?
https://www.fool.com/investing/2024/06/17/could-structure-therapeutics-become-the-next-novo/?source=iedfolrf0000001
Jun 17, 2024 - Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
0